Prognostic models for AML primarily rely on cytogenetic aberrations and molecular abnormalities, such as FLT3-ITD, NPM1, and CEBPA mutations in patients with a normal karyotype [27]. The gene discussed is FLT3; the disease is acute myeloid leukemia.